Clinical trial NCT06868199: A Study of LM-168 as a Single Agent or in Combination With Toripalimab in Subjects With Advanced Solid Tumours
Official title: A Phase I/II, First-in-Human (FIH), Open-Label, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of LM-168 as a Single Agent or in Combination With Toripalimab in Subjects With Advanced Solid Tumours
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: PHASE1
PHASE2
Conditions: Advanced Solid Tumours
Lead sponsor: LaNova Medicines Limited
Sponsor class: INDUSTRY
First posted: 2025-03-10
Enrollment: 87
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SEQUENTIAL
Primary purpose: TREATMENT

Brief summary: For phase I ,this study is to assess the safety and tolerability, obtain the recommended phase 2 dose (RP2D) and/or Maximum Tolerated Dose (MTD) for LM-168 as a single agent or in combination with toripalimab in subjects with advanced solid tumours.

For phase II ,this study is to assess the preliminary anti-tumour activity of LM-168 as a single agent or in combination with toripalimab measured by objective response rate (ORR) in subjects with advanced solid tumours.


Eligibility criteria: Inclusion Criteria:

1. Subjects who are willing to participate in the study and sign the informed consent form (ICF) prior to any procedure.
2. Aged ≥18 years old (including boundary values) , male or female.
3. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
4. Life expectancy ≥ 3 months.
5. In dose escalation stage, subjects must have histological or cytological confirmation of recurrent or refractory advanced solid tumours, and have progressed on standard therapy, or are intolerable for available standard therapy, or there is no available standard therapy.
6. In dose expansion stage, subjects must have histological or cytological confirmation of selected advanced solid tumors.
7. Pre-treatment archived tumour tissue or on-treatment tumour biopsy could be provided for biomarker analysis optionally.
8. At least one measurable disease.
9. Subjects must show appropriate organ and marrow function in laboratory examinations within 7 days prior to the first dose.
10. Subjects who are able to communicate well with investigators and understand and adhere to the requirements of this study.

Exclusion Criteria:

1. Participate in any other clinical trial within 28 days prior to 1st dosing of LM-168.
2. Having received prior the same target or any other immunotherapy or immune-oncology (IO) agent within 28 days of commencing treatment with LM-168.
3. Subjects who have received the anti-tumor treatments within the specified time periods prior to the first dosing of LM-168.
4. Any adverse event from prior anti-tumour therapy has not yet recovered to ≤ grade 1 of CTCAE v5.0.
5. Subjects with uncontrolled tumour-related pain.
6. Subjects with known central nervous system (CNS) or meningeal metastasis.
7. Subjects who have uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures.
8. Subjects with esophageal or gastric varices requiring immediate intervention, or those with a history of variceal bleeding.
9. Hepatic encephalopathy, hepatorenal syndrome, Child-Pugh class B or more severe liver cirrhosis.
10. Tumor invasion of surrounding vital organs or a risk of developing esophagotracheal fistula or esophagopleural fistula.
11. Patients with a history of active or previously confirmed inflammatory bowel disease.
12. Subjects who experienced grade 3 or higher hypersensitivity to the treatment that contains monoclonal antibody.
13. Subjects who previously experienced grade ≥ 3 immune-related adverse events during immunotherapy, as well as subjects who discontinued prior immunotherapy due to severe or life-threatening immune-related adverse events.
14. Subjects who take systemic corticosteroids (\> 10 mg daily prednisone equivalents) or other systemic immunosuppressive medications within 2 weeks prior to the first dosing of LM-168.
15. Subjects with the known history of autoimmune disease.
16. Subjects with the history of idiopathic pulmonary fibrosis, organizing pneumonia , drug-induced pneumonitis, idiopathic pneumonitis, interstitial lung disease, severe radiation pneumonitis or evidence of active pneumonitis on screening chest CT scan.
17. Use of any live attenuated vaccines within 28 days prior to 1st dosing of LM-168.
18. Current or recent use of aspirin (\> 325 mg/day) or treatment with dipyramidole, ticlopidine, clopidogrel, and cilostazol.
19. Current unstable of full-dose oral or parenteral anticoagulants or thrombolytic agents for \> 2 weeks prior to the first dose of LM-168.
20. Subjects who received major surgery or interventional treatment within 28 days prior to 1st dosing of LM-168 (excluding tumour biopsy, puncture, etc.).
21. Subjects who have severe cardiovascular disease.
22. Subjects who have uncontrolled or severe illness.
23. Subjects who have a history of immunodeficiency disease.
24. HIV infection, active infection including tuberculosis, HBV and HCV infection.
25. Subjects with a history of other malignancies within 5 years prior to the first administration of the study drug.
26. Child-bearing potential female who have positive results in pregnancy test or are lactating.
27. Subjects who have psychiatric illness or disorders that may preclude study compliance.
28. Subject who is judged as not eligible to participate in this study by the investigator.

Primary outcomes:
measure: Incidence of adverse events (AEs)
timeFrame: 78 weeks
measure: Incidence of dose-limitingtoxicity (DLT)
timeFrame: 78 weeks
measure: Incidence of serious adverse event (SAE)
timeFrame: 78 weeks
measure: Temperature (Celsius)
timeFrame: 78 weeks
measure: Pulse in BPM(Beat per Minute)
timeFrame: 78 weeks
measure: Blood Pressure in mmHg
timeFrame: 78 weeks
measure: Weight in Kg
timeFrame: 78 weeks
measure: Height in centimeter
timeFrame: 78 weeks
measure: Blood Routine examination
timeFrame: 78 weeks
measure: Urine Routine test
timeFrame: 78 weeks
measure: Blood biochemistry test
timeFrame: 78 weeks
measure: Coangulation function test
timeFrame: 78 weeks
measure: Thyroid function test
timeFrame: 78 weeks
measure: Echocardiography- LVEF(Left Ventricular Ejection Fraction) in percentage
timeFrame: 78 weeks
measure: 12-lead electrocardiogram (ECG) in HR
timeFrame: 78 weeks
measure: 12-lead electrocardiogram (ECG) in RR
timeFrame: 78 weeks
measure: 12-lead electrocardiogram (ECG) in PR
timeFrame: 78 weeks
measure: 12-lead electrocardiogram (ECG) in QRS
timeFrame: 78 weeks
measure: 12-lead electrocardiogram (ECG) in QT
timeFrame: 78 weeks
measure: 12-lead electrocardiogram (ECG) in QTcF
timeFrame: 78 weeks
measure: ECOG(Eastern Cooperative Oncology Group) score
timeFrame: 78 weeks
measure: Objective Response Rate (ORR)
timeFrame: From 78th week to 130th week (52 weeks in total)
Secondary outcomes:
measure: Objective Response Rate (ORR)
timeFrame: 78 weeks
measure: Pharmacokinetic (PK) Parameter: Maximum Observed Concentration (Cmax)
timeFrame: 130 weeks
measure: PK Parameter:Time of Maximum Observed Concentration (Tmax)
timeFrame: 130 weeks
measure: PK Parameter: Area Under the Concentration-time Curve(AUC)
timeFrame: 130 weeks
measure: PK Parameter: Steady State Maximum Concentration(Cmax,ss) PK Parameter: Steady State Maximum Concentration(Cmax,ss)
timeFrame: 130 weeks
measure: PK Parameter: Steady State Minimum Concentration(Cmin,ss)
timeFrame: 130 weeks
measure: PK Parameter: Systemic Clearance at Steady State (CLss)
timeFrame: 130 weeks
measure: PK Parameter: Accumulation Ratio (Rac)
timeFrame: 130 weeks
measure: PK Parameter: Elimination Half-life (t1/2)
timeFrame: 130 weeks
measure: PK Parameter: Volume of Distribution at Steady-State (Vss)
timeFrame: 130 weeks
measure: PK Parameter: Degree of Fluctuation (DF)
timeFrame: 130 weeks
measure: Immunogenicity testing
timeFrame: 130 weeks
measure: Duration of Response (DOR) in Month
timeFrame: 130 weeks
measure: Disease control rate (DCR) in percentage
timeFrame: 130 weeks
measure: progression-free survival (PFS) in Month
timeFrame: 130 weeks
measure: Changes of target lesions from baseline in Millimeter
timeFrame: 130 weeks
measure: Temperature (Celsius)
timeFrame: From 78th week to 130th week (52 weeks in total)
measure: Pulse in BPM(Beat per Minute)
timeFrame: From 78th week to 130th week (52 weeks in total)
measure: Blood Pressure in mmHg
timeFrame: From 78th week to 130th week (52 weeks in total)
measure: Weight in Kg
timeFrame: From 78th week to 130th week (52 weeks in total)
measure: Height in centimeter
timeFrame: From 78th week to 130th week (52 weeks in total)
measure: Blood Routine examination
timeFrame: From 78th week to 130th week (52 weeks in total)
measure: Urine Routine test
timeFrame: From 78th week to 130th week (52 weeks in total)
measure: Blood biochemistry test
timeFrame: From 78th week to 130th week (52 weeks in total)
measure: Coangulation function test
timeFrame: From 78th week to 130th week (52 weeks in total)
measure: Thyroid function test
timeFrame: From 78th week to 130th week (52 weeks in total)
measure: Echocardiography- LVEF(Left Ventricular Ejection Fraction) in percentage
timeFrame: From 78th week to 130th week (52 weeks in total)
measure: ECOG(Eastern Cooperative Oncology Group) score
timeFrame: From 78th week to 130th week (52 weeks in total)
Other outcomes:
Locations:
city: Wollongong
country: Australia
facility: Cancer Care Wollongong
state: New South Wales
city: Birtinya
country: Australia
facility: Sunshine Coast University Private Hospital
state: Queensland
Study officials:
affiliation: LaNova Medicines Limited
name: Sherry Qin
role: STUDY_DIRECTOR
References: